作为潜在新型抗丙型肝炎病毒药物的C-核苷的发现与合成
Discovery and Synthesis of C-Nucleosides as Potential New Anti-HCV Agents.
作者信息
Draffan Alistair G, Frey Barbara, Pool Brett, Gannon Carlie, Tyndall Edward M, Lilly Michael, Francom Paula, Hufton Richard, Halim Rosliana, Jahangiri Saba, Bond Silas, Nguyen Van T T, Jeynes Tyrone P, Wirth Veronika, Luttick Angela, Tilmanis Danielle, Thomas Jesse D, Pryor Melinda, Porter Kate, Morton Craig J, Lin Bo, Duan Jianmin, Kukolj George, Simoneau Bruno, McKercher Ginette, Lagacé Lisette, Amad Ma'an, Bethell Richard C, Tucker Simon P
机构信息
Biota Scientific Management Pty. Ltd. , 10/585 Blackburn Road, Notting Hill, Victoria 3168, Australia.
Research and Development, Boehringer Ingelheim (Canada), Ltd. , 2100 rue Cunard, Laval, Québec H7S 2G5, Canada.
出版信息
ACS Med Chem Lett. 2014 Apr 10;5(6):679-84. doi: 10.1021/ml500077j. eCollection 2014 Jun 12.
Nucleoside analogues have long been recognized as prospects for the discovery of direct acting antivirals (DAAs) to treat hepatitis C virus because they have generally exhibited cross-genotype activity and a high barrier to resistance. C-Nucleosides have the potential for improved metabolism and pharmacokinetic properties over their N-nucleoside counterparts due to the presence of a strong carbon-carbon glycosidic bond and a non-natural heterocyclic base. Three 2'CMe-C-adenosine analogues and two 2'CMe-guanosine analogues were synthesized and evaluated for their anti-HCV efficacy. The nucleotide triphosphates of four of these analogues were found to inhibit the NS5B polymerase, and adenosine analogue 1 was discovered to have excellent pharmacokinetic properties demonstrating the potential of this drug class.
核苷类似物长期以来一直被视为发现用于治疗丙型肝炎病毒的直接作用抗病毒药物（DAA）的潜在药物，因为它们通常表现出跨基因型活性以及对耐药性的高屏障。由于存在强碳 - 碳糖苷键和非天然杂环碱基，C - 核苷相比于它们的N - 核苷类似物具有改善代谢和药代动力学性质的潜力。合成了三种2'CMe - C - 腺苷类似物和两种2'CMe - 鸟苷类似物，并对其抗丙型肝炎病毒疗效进行了评估。发现其中四种类似物的三磷酸核苷酸可抑制NS5B聚合酶，并且发现腺苷类似物1具有优异的药代动力学性质，证明了这类药物的潜力。
Zotero 插件